Table I.
Published trials eligible for the CTT collaborative meta-analyses for which there was agreement in principle for data provision at the time this protocol was finalised
| Treatment comparison and trial acronym⁎ | Treatment comparison (mg/d)† | No. of patients | Median duration of follow-up‡ |
|---|---|---|---|
| Statin vs placebo | |||
| Atorvastatin | |||
| ASCOT-LLA | A10 vs placebo | 10,305 | 3.3 |
| CARDS | A10 vs placebo | 2838 | 4.1 |
| ASPEN | A10 vs placebo | 2410 | 4.0 |
| 4D | A20 vs placebo | 1255 | 4.0 |
| SPARCL | A80 vs placebo | 4731 | 4.9 |
| Fluvastatin | |||
| ALERT | F40 then 80 vs placebo | 2102 | 5.5 |
| LIPS | F80 vs placebo | 1677 | 3.9 |
| Lovastatin | |||
| AFCAPS/TexCAPS | L20-40 vs placebo | 6605 | 5.2 |
| Pravastatin | |||
| WOSCOPS | P40 vs placebo | 6595 | 4.8 |
| CARE | P40 vs placebo | 4159 | 5.0 |
| LIPID | P40 vs placebo | 9014 | 6.0 |
| PROSPER | P40 vs placebo | 5804 | 3.3 |
| Rosuvastatin | |||
| GISSI-HF | R10 vs placebo | 4574 | 4.2 |
| AURORA | R10 vs placebo | 2773 | 4.6 |
| CORONA | R10 vs placebo | 5011 | 3.0 |
| JUPITER | R20 vs placebo | 17,802 | 2.0 |
| Simvastatin | |||
| SSSS | S20-40 vs placebo | 4444 | 5.4 |
| HPS | S40 vs placebo | 20,536 | 5.4 |
| Subtotal (18 trials) | 112,635 | 4.8§ | |
| Statin vs open control or usual care | |||
| ALLIANCE | A10-80 vs usual care | 2442 | 4.7 |
| Post-CABG | L40-80 vs L2 · 5-5 | 1351 | 4.3 |
| MEGA║ | P10-20 vs usual care | 8214 | 5.0 |
| GISSI-P | P20 vs no treatment | 4271 | 2.0 |
| ALLHAT–LLT | P40 vs usual care | 10,355 | 4.9 |
| Subtotal (5 trials) | 26,633 | 4.4§ | |
| More vs less intensive statin therapy | |||
| IDEAL | A40-80 vs S20-40 | 8888 | 4.8 |
| PROVE-IT | A80 vs P40 | 4162 | 2.1 |
| TNT | A80 vs A10 | 10,001 | 5.0 |
| A to Z | S40 then S80 vs placebo then S20 | 4497 | 2.0 |
| SEARCH | S80 vs S20 | 12,064 | 7.0 |
| Subtotal (5 trials) | 39,612 | 5.1§ | |
Trial acronyms (in alphabetical order): AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; ALERT, Assessment of LEscol in Renal Transplantation; ALLHAT-LLT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ALLIANCE, Aggressive Lipid-Lowering Initiation Abates New Cardiac Events; ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm; ASPEN, Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus; A to Z, Aggrastat to Zocor; AURORA, A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events; CARDS, Collaborative Atorvastatin Diabetes Study; CARE, Cholesterol And Recurrent Events; CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure; 4D, Die Deutsche Diabetes Dialyse Studie; GISSI-HF, Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza cardiaca; GISSI-P, Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico Prevenzione; HPS, Heart Protection Study; IDEAL, Incremental Decrease in End Points Through Aggressive Lipid Lowering; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LIPS, Lescol Intervention Prevention Study; LIPID, Long-term Intervention with Pravastatin in Ischaemic Disease; MEGA, Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; Post-CABG, Post-Coronary Artery Bypass Graft; PROSPER, PROspective Study of Pravastatin in the Elderly at Risk; PROVE-IT, Pravastatin or Atorvastatin Evaluation and Infection Therapy; SEARCH, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels; SSSS, Scandinavian Simvastatin Survival Study; TNT, Treating to New Targets; WOSCOPS, West of Scotland Coronary Prevention Study.
Statins tested: A, atorvastatin; F, fluvastatin; L, lovastatin; P, pravastatin; R, rosuvastatin; S, simvastatin.
Estimated using Kaplan-Meier method with patients censored at their date of death.
Weighted by trial-specific variances of observed log-rank (o − e) for major vascular events.
Includes 382 randomized patients who were excluded from the original publication.